Skip to main content

Advertisement

SpringerLink
Log in

Contraception for Breast Feeding Mothers with the 75 Microgram Desogestrel-Only Pill: An Indian Perspective

  • Invited Review Article
  • Published:
The Journal of Obstetrics and Gynecology of India Aims and scope Submit manuscript

A Correction to this article was published on 14 March 2019

This article has been updated

Abstract

Contraception for nursing mothers is an important aspect from the point of view of birth spacing as well as maternal and infant well-being. An ideal contraceptive for this period would be one that is highly efficacious, fairly safe and reversible, with no negative impact on breast milk and infant growth. The 75 microgram (mcg) desogestrel-only pill is the only Progestogen only pill (POP) available in India. The objective of this article is to evaluate if Desogestrel 75 mcg POP stands out as a near ideal method for contraception in the post-partum women by reviewing data available from Indian clinical studies primarily and also some evidences from international studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 14 March 2019

    This matter was investigated by the Editor-in-Chief of the journal and based on the investigation this correction is being published. The Journal of Obstetrics and Gynecology of India does not support publication of pharmaceutical company-sponsored articles. The co-author of this article has declared a conflict of interest as an employee of the manufacturing company of the drug helped in this review, and hence, readers are advised to take into account a possible bias.

References

  1. International Institute for Population Sciences (IIPS) and Macro International. National Family Health Survey (NFHS-3), 2005–06: India: Volume I. Mumbai: IIPS;2007. http://www.measuredhs.com/pubs/pdf/FRIND3/00FrontMatter00.pdf. Accessed 3 June 2014.

  2. Marston Cicely. Report of a WHO Technical Consultation on Birth Spacing Geneva Switzerland 13–15 June 2005. Geneva, Switzerland, World Health Organization [WHO], 2006. 37 p http://www.who.int/maternal_child_adolescent/documents/birth_spacing.pdf. Accessed 18 June 2014.

  3. García PV, Mella C. Analysis of factors involved in lactational amenorrhea. J Biosaf Health Educ. 2013;1(109):2332-–0893.

    Google Scholar 

  4. National guidelines on infant and young child feeding. Ministry of Human Resource Development. Department of Women and Child development (Food and Nutrition Board). Government of India.; 2004. p 2–3. http://wcd.nic.in/nationalguidelines.pdf.Accessed 3 June 2014.

  5. WBTi: India Report 2012 (World Breast feeding Trends Initiative) http://www.worldbreastfeedingtrends.org/report/WBTi-India-2012.pdf. Accessed 3 June 2014.

  6. Flynn AM, Docker M, Brown JB, et al. Ultrasonographic patterns of ovarian activity during breastfeeding. Am j obst Gynecol. 1991;165(6 Pt 2):2027–31.

    Article  CAS  Google Scholar 

  7. World Health Organization. Medical eligibility criteria for contraceptive use; 2004. Reproductive Health and Research, World Health Organization WHO/RHR/00.02, Geneva (2008).

  8. Vessey M, Lawless M, Yeates D. Efficacy of different contraceptive methods. Lancet. 1982;319(8276):841–2.

    Article  Google Scholar 

  9. Cerazette® Patient Information booklet 2014.

  10. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 1988;38(3):325–32.

    Article  CAS  PubMed  Google Scholar 

  11. The Medical Eligibility Criteria Wheel for Contraceptive use––India (2010) (India MEC Wheel)––Govt of India (Adopted from WHO Medical Eligibility Criteria for Contraceptive Use, 3rd Edition 2004 and 2008 Update).

  12. Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception. 1997;55(6):347–50.

    Article  CAS  PubMed  Google Scholar 

  13. Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and Levonorgestrel 30 μg daily. Hum Reprod. 1999;14(4):982–5.

    Article  CAS  PubMed  Google Scholar 

  14. Ray Subrat, Sovani VB. A postmarketing observational study assessing acceptability and reliability of desogestrel only contraceptive pill (Cerazette) in Indian women. J Indian Med Assoc. 2006;104(11):653–6.

    PubMed  Google Scholar 

  15. Dutta DK, Dutta I. Desogestrel mini pill: is this safe in lactating mother? J Indian Med Assoc. 2013;111(8):553–5.

    PubMed  Google Scholar 

  16. Korver T. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day: collaborative study group on the desogestrel-containing progestogen-only pill. Eur J Contracept Reprod Health Care. 1998;3(4):169–78.

    Article  CAS  Google Scholar 

  17. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 μg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-h delays in tablet intake. Contraception. 2005;71(1):8–13.

    Article  CAS  PubMed  Google Scholar 

  18. Bjarnadóttir RI, Gottfredsdóttir H, Sigurdardóttir K, et al. Comparative study of the effects of a progestogen‐only pill containing desogestrel and an intrauterine contraceptive device in lactating women. BJOG: Int J Obst Gynaecol. 2001;108(11):1174–80.

    Google Scholar 

  19. Kovacs Gab. Progestogen-only pills and bleeding disturbances. Hum Reprod. 1996;11(suppl 2):20–3.

    Article  PubMed  Google Scholar 

  20. Belsey EM, d’Arcangues Catherine. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 1986;34(3):253–60.

    Article  CAS  PubMed  Google Scholar 

  21. Bitzer J, Gemzell-Danielsson K, Roumen F, et al. “The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care. 2012;17(1):65–78.

    Article  PubMed  Google Scholar 

  22. Sheriar N, Joshi R, Mukherjee B, et al. Impact of structured counseling on the selection of hormonal contraceptive methods: results of a multi-centric, observational study in India. J Obst Gynaecol India. 2014;64(4):1–10.

    Google Scholar 

  23. Merki-Feld GS, Imthurn B, Seifert B, et al. Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine. Eur J Contracept Reprod Health Care. 2013;18(5):394–400.

    Article  PubMed  Google Scholar 

  24. Ahrendt HJ, Karckt U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care. 2007;12(4):354–61.

    Article  CAS  PubMed  Google Scholar 

  25. Morotti M, Buccelli E, Valentino R, et al. M054 Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Int J of Gyn Obs. 2012 Oct; 119:S548. Available from: http://dx.doi.org/10.1016/s0020-7292(12)61248-x.

Download references

Compliance with Ethical Requirements and Conflict of Interest

This manuscript is a review article, does not include any patient data and hence did not require an approval by an ethics committee. Dr. Sheela Mane and Dr. Meera Ragavan declare no conflict of interest or funding relevant to this manuscript that may bias their opinion. Dr. Saravanan Veeramalai is an employee of MSD Pharmaceuticals Private Limited.

Author information

Authors and Affiliations

  1. Fortis Hospitals and Anugraha Nursing Home, Bangalore, India

    Sheela Mane (Senior Consultant (OB & GYN)

  2. MSD Pharmaceuticals PVT LTD, Chennai, India

    Saravanan Veeramalai (Manager Medical Affairs)

  3. Apollo Hospitals PVT LTD, Chennai, India

    Meera V. V. Ragavan (Consultant Obstetrician and Urogynecologist)

  4. MSD Pharmaceuticals Private Limited (A Subsidiary of Merck & Co. Inc.), Whitehouse Station, NJ, USA

    Saravanan Veeramalai (Manager Medical Affairs)

  5. 10th Floor, Platina Bldg, Next To Citi Bank, C-59, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai, 400 098, India

    Saravanan Veeramalai (Manager Medical Affairs)

Authors
  1. Sheela Mane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saravanan Veeramalai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meera V. V. Ragavan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saravanan Veeramalai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mane, S., Veeramalai, S. & Ragavan, M.V.V. Contraception for Breast Feeding Mothers with the 75 Microgram Desogestrel-Only Pill: An Indian Perspective. J Obstet Gynecol India (2014). https://doi.org/10.1007/s13224-014-0633-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13224-014-0633-1

Keywords

Search

Navigation